New Antibody for Prostate Cancer Diagnosis
Author Information
Author(s): A.M.R. Haines, S.E. Larkin, A.P. Richardson, R.W. Stirling, E. Heyderman
Primary Institution: Department of Histopathology, UMDS, St Thomas's Hospital, London, UK
Hypothesis
Can a monoclonal antibody to prostatic acid phosphatase improve the diagnosis of prostate cancer?
Conclusion
The monoclonal antibody PASE/4LJ is effective for immunostaining prostatic tissues and does not inhibit prostatic acid phosphatase activity.
Supporting Evidence
- The antibody successfully stained all primary and metastatic prostatic carcinomas.
- Positivity was observed in some non-prostatic malignant tissues, but staining was weaker than in prostatic tissues.
- The antibody did not inhibit the enzyme activity of prostatic acid phosphatase.
Takeaway
Scientists created a special antibody that helps doctors see prostate cancer better in tissue samples.
Methodology
The study involved immunostaining various tissue sections with the monoclonal antibody PASE/4LJ and assessing its reactivity.
Limitations
The antibody did not stain canine prostates, and its effectiveness in some non-prostatic malignancies was limited.
Want to read the original?
Access the complete publication on the publisher's website